AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® in Patients with Metastatic NSCLC

Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer

AstraZeneca PLC said that Imfinzi, in combination with standard-of-care chemotherapy, was much better than chemotherapy alone in trials on patients with advanced biliary tract cancer (BTC). The candidate demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit, so an independent monitoring committee confirmed it has met the main goal of the late-stage clinical studies.

AstraZeneca posts stellar late-stage trial results for advanced biliary tract cancer candidate

AstraZeneca's therapy could have at least one major advantage.

Can AstraZeneca's COVID Antibody Therapy Win Against Regeneron and Eli Lilly?

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Bob Harper Unveil the Survivors Have Heart Second Chance Portraits to Change the Face of Heart Attack Survivorship.

AstraZeneca and Bob Harper Unveil the Survivors Have Heart Second Chance Portraits to Change the Face of Heart Attack Survivorship

Merck

Moderna has likely peaked. There are much safer growth stocks to buy right now.

2 COVID Stocks I'd Consider Instead of Moderna

AstraZeneca PLC is the best bet in the pharma sector according to analysts at JP Morgan and even after a recent share price recovery there is still lots of value to be had, says the US bank. The pharma's medium-term growth prospects are yet to be fully reflected in the Anglo-Swedish group's valuation, said the bank in a note.

AstraZeneca 'top pick' in pharma sector as JP Morgan predicts big growth ahead

AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit Amgen Inc (NASDAQ: AMGN) with a clinical hold on its MCL-1 inhibitor AMG 397 following signs of cardiac toxicity.

AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the third annual Cancer Community Awards (or C2 Awards). A part of the AstraZeneca YOUR Cancer program, the C2 Awards celebrate diverse individuals and organizations creating meaningful change in the lives of people with cancer and their loved ones across five unique categories. This year, a new Catalyst for Equity Award category was introduced to recognize those

AstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community Awards

Unilever

Shares of COVID-19 vaccine maker AstraZeneca PLC (NASDAQ: AZN) along with other multinational British companies such as Unilever PLC (NYSE: UL), Diageo PLC (NYSE: DEO), HSBC Holdings PLC (NYSE: HSBC), and Royal Dutch Shell PLC (NYSE: RDS-A), all experienced a drop in their stock prices on Monday as the ongoing energy crisis consumes Britain.  What Happened: The FTSE 100 exchange in London traded  30.2 points down from Friday's close of 7,234.03 at the time of writing on Monday, representing a drop of 0.4%.

AstraZeneca, Unilever Tumble As FTSE 100 Struggles With Rising Energy Prices

Pfizer

Two doses of either the vaccine made by Pfizer PFE, -0.43% and BioNTech [s:bntx] or Oxford-AstraZeneca AZN, +0.92% vaccines provided a similar level of protection to prior natural infection when the Delta variant was dominant, the U.K. Office of National Statistics said Monday. Vaccination significantly reduced the risk of people testing positive during both the Alpha-dominant period and the Delta-dominant period, but effectiveness was reduced in the Delta-dominant period compared with the Alpha-dominant period.

Pfizer and AstraZeneca vaccines were effective as prior infection, U.K. study finds

Will AstraZeneca Have a Big Market for Its COVID-19 Therapy?

Ford Motor Company

NextEra Energy

A relatively small amount of money invested in great businesses can generate sizable returns over the long run.

The Smartest Stocks to Buy With $200 Right Now.

AstraZeneca PLC said a final phase trial using a combination of tremelimumab and Imfinzi (durvalumab) showed an improved survival rate for patients with liver cancer. The HIMALAYA Phase III trial, where a single, high priming dose of tremelimumab, an anti-CTLA4 antibody, was added to Imfinzi, demonstrated a statistically significant and clinically meaningful overall survival benefit versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC), who had not received prior systemic therapy and were not eligible for localised treatment.

AstraZeneca says phase III trial shows Imfinzi and tremelimumab combination improves liver cancer survival rate

It may not be a matter of if, but a matter of how high.

Is AstraZeneca Set to Soar With an Advanced Breast Cancer Treatment?

Australian biotech CSL said on Thursday it was committed to its agreement for the production of about 50 million doses of AstraZeneca's COVID-19 vaccine into 2022.

Australia's CSL reaffirms commitment to making AstraZeneca COVID vaccine

Baidu

British American Tobacco

JD.com

Petroleo Brasileiro

Rio Tinto plc Sponsored

STMicroelectronics NV ADR RegS

U.S. investors looking to diversify their portfolio to maximize long-term returns may want to consider these top foreign stocks right now. The post 7 Foreign Stocks All U.S. Investors Should Be Watching appeared first on InvestorPlace.

7 Foreign Stocks All U.S. Investors Should Be Watching

AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease or death in a late-stage study. The drug, a cocktail of two antibodies called AZD7442, reduced the risk of severe COVID-19 or death by 50% in non-hospitalized patients who have had symptoms for seven days or less, meeting the primary goal of the study.

AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial

AstraZeneca (AZN) posts positive results from the phase III TACKLE study on the AZD7442 combo for treating mild-to-moderate COVID-19 in the outpatient setting. The study has met its primary endpoint.

AstraZeneca (AZN) COVID-19 Antibody Meets Goal in TACKLE Study

AstraZeneca PLC's investment in research and development is more than paying off, according to a boutique investment bank. Berenberg on Monday lifted its price target for the stock to £105 from £100, repeating its 'buy' advice.

AstraZeneca's investment in research and development is paying off but market is yet to fully recognise its potential, says investment bank

The global tally of confirmed cases of the coronavirus-borne illness COVID-19 edged closer to 238 million on Monday, as Merck submitted an application to the Food and Drug Administration for emergency authorization of what would be the first pill-based treatment for the deadly illness.

Coronavirus Update: Merck seeks authorization for what would be first pill to treat COVID-19, and AstraZeneca reports positive results for antibody treatment

AstraZeneca has already requested FDA authorization for its injection, AZD7442, to prevent COVID-19 - new results show it might treat the disease too.

AstraZeneca says its COVID-19 drug cuts the risk of severe disease in half. It's the first antibody cocktail shown to both prevent and treat the disease in late-stage trials.

AstraZeneca says its experimental antibody drug cocktail can reduce the risk by 50% in patients who had been symptomatic for less than seven days.

AstraZeneca Says Drug Cocktail Effective in Reducing Risk of Developing Severe Covid-19

The British pharma firm has already asked U.S. regulators for emergency approval to use the antibody cocktail to prevent symptomatic Covid-19.

AstraZeneca's Injectable Antibody Cocktail Halves Risk Of Death Or Developing Severe Covid, Trial Finds

AstraZeneca's new long- acting antibody (LAAB) treatment halved the risk of death or catching severe Covid-19 in a phase III trial of people with mild symptoms, the pharma giant said today. This trial, TACKLE, combined with results from a previous study PROVENT, show that the treatment, called AZD7442, is both effective against COVID-19 infections as well as preventing the virus, said Astra.

AstraZeneca antibody treatment halves Covid-19 deaths in new trial

AstraZeneca: Long-acting COVID antibody shown to prevent severe disease, death

News for AstraZeneca Stock (AZN)